Table 3 Thyroid function characteristics of patients treated with regorafenib (n = 35)
From: Managing adherence, exposure, and toxicity in oral anticancer therapies
Number of patients with abnormal TSH elevation (%) | 15 (42.8) |
|---|---|
Maximal TSH level (mU/L) (%) | |
3.68–9.99 | 11 (31.4) |
10.00 or higher | 4 (11.4) |
Number of patients receiving levothyroxine sodium hydrate (%) | 3 (8.5) |
Number of patients with abnormal FT4 decrease (%) | 2 (5.7) |
Number of patients with abnormal FT3 decrease (%) | 4 (11.4) |
Number of patients with hypothyroidism | 2 ( 5.7) |
Number of patients with subclinical hypothyroidism | 13 (37.1) |